These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 18594135)

  • 1. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
    [No Abstract]   [Full Text] [Related]  

  • 2. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
    Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
    Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel therapies for immune tolerance in haemophilia A.
    Collins PW
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
    Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
    Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor development.
    Astermark J; Lacroix-Desmazes S; Reding MT
    Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII inhibitors: a 50-year perspective.
    Green D
    Haemophilia; 2011 Nov; 17(6):831-8. PubMed ID: 21592257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
    Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
    Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
    Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
    Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.